Hemostemix Inc. (CVE:HEM – Get Free Report) was down 20% during trading on Monday. The company traded as low as C$0.04 and last traded at C$0.04. 145,275 shares were traded during mid-day trading, an increase of 236% from the average session volume of 43,224 shares. The stock had previously closed at C$0.05.
Hemostemix Stock Down 30.0%
The company has a 50 day simple moving average of C$0.06 and a two-hundred day simple moving average of C$0.07. The firm has a market capitalization of C$7.40 million, a P/E ratio of -1.35 and a beta of -0.14. The company has a current ratio of 0.13, a quick ratio of 0.48 and a debt-to-equity ratio of -61.85.
About Hemostemix
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Recommended Stories
- Five stocks we like better than Hemostemix
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
